Pavithra Nedumaran
Research Subjects
Pavithra Nedumaran has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Bharadwaj
Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States
1 shared publication Aleksandar B. Stotland
1 shared publication- Ashley Dinh
Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA 90048; Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048
1 shared publication - Deepika Rai
Advanced Clinical Biosystems Research Institute, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California
1 shared publication - Divya Gupta1 shared publication
- Honit Piplani
Cibus Therapeutics, Palo Alto, California
1 shared publication
Latest Publications
- Open Access
- 11 June 2026
- Published by Elsevier in SSRN Electronic Journal
Asporin Improves Cardiac Myocyte Response to Ischemia and Reperfusion Stress
Myocardial-Infarction (MI) remains a leading cause of mortality worldwide, despite advancements in clinical therapies and interventions. MI results from prolonged ischemia, leading to hypoxia-induced damage to cardiac tissue and reperfusion-injury (R/I) that aggravates cardiomyocyte (CM) loss. One key cellular event during this process is the accumulation of dysfunctional mitochondria, resulting from environmental hypoxia and subsequent oxidative stress upon reperfusion. Post-MI cardiac-remodeling involves changes in both cellular and extracellular matrix (ECM). Ubiquitin-dependent and independent autophagy are crucial for cardio-protection during this phase. Asporin (ASPN), a small leucine-rich proteoglycan, modulates cardiac remodeling by limiting excessive fibrosis and protecting CMs from cell death. We investigated the therapeutic potential of ASPN using an exogenous recombinant ASPN-peptide (rASPN) and tested its effects in an in-vitro ischemia-reperfusion (I/R) model simulating MI conditions. Two I/R models were developed using an immortalized human embryonic cardiac cell line to reflect the hypoxia-reperfusion (H/R) phases of MI. In the No-Reoxygenation (No-ReOx) model, cells were subjected to hypoxia for 18-hours, with or without exogenous rASPN. In the Reoxygenation (ReOx) model, cells underwent 18-hours of hypoxia, followed by 12-hours of reoxygenation (simulating reperfusion), with or without rASPN. Proteomics revealed that ASPN modulates pathways involved in apoptosis, non-canonical autophagy, and metabolic reprogramming. Additionally, ASPN influenced immune-response pathways and significantly affected TGF-β signaling, a central mediator of cardiac fibrosis and remodeling post-MI. Our study demonstrates that rASPN confers protection in a human cardiac cell-based H/R model, highlighting its therapeutic potential as a biological or peptide-based intervention to mitigate R/I and adverse remodeling following MI.
- 11 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAsporin Improves Cardiac Myocyte Response to Ischemia and Reperfusion Stress
Myocardial-Infarction (MI) remains a leading cause of mortality worldwide, despite advancements in clinical therapies and interventions. MI results from prolonged ischemia, leading to hypoxia-induced damage to cardiac tissue and reperfusion-injury (R/I) that aggravates cardiomyocyte (CM) loss. One key cellular event during this process is the accumulation of dysfunctional mitochondria, resulting from environmental hypoxia and subsequent oxidative stress upon reperfusion. Post-MI cardiac-remodeling involves changes in both cellular and extracellular matrix (ECM). Ubiquitin-dependent and independent autophagy are crucial for cardio-protection during this phase. Asporin (ASPN), a small leucine-rich proteoglycan, modulates cardiac remodeling by limiting excessive fibrosis and protecting CMs from cell death. We investigated the therapeutic potential of ASPN using an exogenous recombinant ASPN-peptide (rASPN) and tested its effects in an in-vitro ischemia-reperfusion (I/R) model simulating MI conditions. Two I/R models were developed using an immortalized human embryonic cardiac cell line to reflect the hypoxia-reperfusion (H/R) phases of MI. In the No-Reoxygenation (No-ReOx) model, cells were subjected to hypoxia for 18-hours, with or without exogenous rASPN. In the Reoxygenation (ReOx) model, cells underwent 18-hours of hypoxia, followed by 12-hours of reoxygenation (simulating reperfusion), with or without rASPN. Proteomics revealed that ASPN modulates pathways involved in apoptosis, non-canonical autophagy, and metabolic reprogramming. Additionally, ASPN influenced immune-response pathways and significantly affected TGF-β signaling, a central mediator of cardiac fibrosis and remodeling post-MI. Our study demonstrates that rASPN confers protection in a human cardiac cell-based H/R model, highlighting its therapeutic potential as a biological or peptide-based intervention to mitigate R/I and adverse remodeling following MI.